A xenograft model of HNSCC identified a HER4-activating oncogenic mutation leading to increased HER4 phosphorylation, which suggested that it may activate other HERs as a heterodimer and predict sensitivity to afatinib33. This evidence concerns the gene ERBB4 and head and neck squamous cell carcinoma.